[go: up one dir, main page]

AR132028A2 - Proceso de producción de un compuesto intermediario de diazabiciclo [3.2.1]octano-2-carboxamida - Google Patents

Proceso de producción de un compuesto intermediario de diazabiciclo [3.2.1]octano-2-carboxamida

Info

Publication number
AR132028A2
AR132028A2 ARP240100515A ARP240100515A AR132028A2 AR 132028 A2 AR132028 A2 AR 132028A2 AR P240100515 A ARP240100515 A AR P240100515A AR P240100515 A ARP240100515 A AR P240100515A AR 132028 A2 AR132028 A2 AR 132028A2
Authority
AR
Argentina
Prior art keywords
octane
alkyl
intermediate compound
protecting group
heterocyclyl
Prior art date
Application number
ARP240100515A
Other languages
English (en)
Inventor
Takao Abe
Takeshi Furuuchi
Yoshiaki Sakamaki
Nakako Mitsuhashi
Yumiko Saito
Original Assignee
Meiji Seika Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Pharma Co Ltd filed Critical Meiji Seika Pharma Co Ltd
Publication of AR132028A2 publication Critical patent/AR132028A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Un proceso para producir un compuesto intermediario de diazabiciclo [3.2.1]octano-2-carboxamida representado por la fórmula (VII), en donde R³ es alquilo C₁₋₆ o heterociclilo, R³ se puede modificar con 0 a 5 R⁴, R⁴ se puede sustituir consecutivamente, aquí, R⁴ es alquilo C₁₋₆, heterociclilo, R⁵(R⁶)N- o un grupo protector, R⁵ y R⁶ son cada uno, de modo independiente, hidrógeno o alquilo C₁₋₆ o forman juntos heterociclilo, por otra parte, R³, R⁵ y R⁶ se pueden someter a cierre del anillo en una posición arbitraria; a partir del grupo de fórmula (VI) que comprende en un caso en que la cadena lateral de R³ONHC(=O)- tenga un grupo protector, eliminación del grupo protector con un ácido y precipitación de un producto crudo por adición de un solvente pobre a la solución de reacción para obtener un compuesto crudo representado por la anterior fórmula (VII).
ARP240100515A 2013-10-08 2024-03-01 Proceso de producción de un compuesto intermediario de diazabiciclo [3.2.1]octano-2-carboxamida AR132028A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013211242 2013-10-08

Publications (1)

Publication Number Publication Date
AR132028A2 true AR132028A2 (es) 2025-05-21

Family

ID=52813113

Family Applications (4)

Application Number Title Priority Date Filing Date
ARP140103759A AR097971A1 (es) 2013-10-08 2014-10-08 Formas cristalinas de derivado de diazabiciclooctano y proceso de producción de ellas
ARP240100515A AR132028A2 (es) 2013-10-08 2024-03-01 Proceso de producción de un compuesto intermediario de diazabiciclo [3.2.1]octano-2-carboxamida
ARP240100516A AR132029A2 (es) 2013-10-08 2024-03-01 Proceso de producción de un compuesto intermediario de diazabiciclo [3.2.1]octano-2-carboxamida
ARP240100517A AR132030A2 (es) 2013-10-08 2024-03-01 Proceso de producción de formas cristalinas de derivado de diazabiciclooctano

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP140103759A AR097971A1 (es) 2013-10-08 2014-10-08 Formas cristalinas de derivado de diazabiciclooctano y proceso de producción de ellas

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP240100516A AR132029A2 (es) 2013-10-08 2024-03-01 Proceso de producción de un compuesto intermediario de diazabiciclo [3.2.1]octano-2-carboxamida
ARP240100517A AR132030A2 (es) 2013-10-08 2024-03-01 Proceso de producción de formas cristalinas de derivado de diazabiciclooctano

Country Status (22)

Country Link
US (5) US10131665B2 (es)
EP (4) EP3613741A1 (es)
JP (3) JP6617029B2 (es)
KR (2) KR102388529B1 (es)
CN (2) CN111153903A (es)
AR (4) AR097971A1 (es)
AU (1) AU2014332960B2 (es)
BR (2) BR112016006266B1 (es)
CA (2) CA2926071C (es)
DK (1) DK3067355T3 (es)
ES (2) ES2842225T3 (es)
HK (1) HK1219479A1 (es)
HU (1) HUE051925T2 (es)
IL (2) IL244969B (es)
MX (2) MX383661B (es)
MY (1) MY199066A (es)
NZ (5) NZ719568A (es)
RU (1) RU2695219C2 (es)
SG (1) SG11201602723RA (es)
TW (1) TWI673269B (es)
WO (1) WO2015053297A1 (es)
ZA (1) ZA201602054B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2857401B8 (en) * 2012-05-30 2019-11-20 Meiji Seika Pharma Co., Ltd. NOVEL ß-LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME
US10000491B2 (en) * 2013-09-24 2018-06-19 Meiji Seika Pharma Co., Ltd. Process for producing diazabicyclooctane derivative and intermediate thereof
NZ719568A (en) 2013-10-08 2018-06-29 Meiji Seika Pharma Co Ltd Crystals of diazabicyclooctane derivative and production method for crystals of diazabicyclooctane derivative
AU2015355970B2 (en) 2014-12-05 2020-05-21 Meiji Seika Pharma Co., Ltd. Method for producing crystals of diazabicyclooctane derivative and stable lyophilized preparation
US10208041B2 (en) * 2016-10-07 2019-02-19 Hoffman-La Roche Inc. Diazabicyclooctane compounds
CN115745910B (zh) 2017-07-21 2025-05-27 安塔比奥公司 化学化合物
CN111447924A (zh) * 2017-09-27 2020-07-24 费多拉制药公司 二氮杂二环辛烷衍生物的药物形式及其制备方法
WO2019064066A1 (en) 2017-09-27 2019-04-04 F. Hoffmann-La Roche Ag PHARMACEUTICAL FORMS OF DIAZABICYCLOOCTANE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
WO2019064071A1 (en) 2017-09-27 2019-04-04 F. Hoffmann-La Roche Ag CRYSTALLINE FORMS OF DIAZABICYCLOOCTANE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
CN107991404B (zh) * 2017-11-23 2021-01-08 中山奕安泰医药科技有限公司 一种(2s,5r)-苄氧胺基哌啶-2-甲酰胺的检测方法
CN107941944B (zh) * 2017-11-23 2020-09-15 中山奕安泰医药科技有限公司 一种(2s,5r)-苄氧胺基哌啶-2-甲酸乙酯草酸盐的检测方法
EP3572411A1 (en) 2018-05-21 2019-11-27 Antabio SAS Thiazole derivatives as metallo-beta-lactamase inhibitors
CN119707784A (zh) * 2018-09-21 2025-03-28 株式会社Api 氨基酸衍生物的制备方法
EP4180106A4 (en) * 2020-07-13 2024-08-28 NGK Insulators, Ltd. PURIFICATION PROCESS
CN113552250A (zh) * 2021-06-30 2021-10-26 海南海灵化学制药有限公司 一种盐酸头孢唑兰的杂质检测方法
WO2024263708A2 (en) * 2023-06-23 2024-12-26 Board Of Trustees Of Michigan State University Ornithine decarboxylase (odc) inhibitors and uses thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5038509B1 (es) 1970-10-21 1975-12-10
GB1589317A (en) 1977-11-24 1981-05-13 Lilly Co Eli Freeze drying cephalothin sodium
JPS6019759B2 (ja) 1977-11-24 1985-05-17 イ−ライ・リリ−・アンド・カンパニ− 非経口投予用11115152139199東京都中央区京橋2丁目3番13号
JPS60255723A (ja) 1984-05-31 1985-12-17 Ono Pharmaceut Co Ltd メシル酸ガベキサートの結晶性凍結乾燥製剤及びその製造方法
JPH07117533B2 (ja) 1985-08-28 1995-12-18 株式会社生体科学研究所 トランスフエリンおよびその用途
US20030220521A1 (en) 1989-07-27 2003-11-27 G.D. Searle & Co. Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension
TW264475B (es) 1991-09-20 1995-12-01 Takeda Pharm Industry Co Ltd
JP2843444B2 (ja) 1994-05-02 1999-01-06 塩野義製薬株式会社 ピロリジルチオカルバペネム誘導体の結晶,該結晶を含む凍結乾燥製剤,およびその製造方法
CN1048248C (zh) 1994-05-02 2000-01-12 盐野义制药株式会社 吡咯烷基硫基碳代青霉烯衍生物的结晶、含该结晶的冷冻干燥制剂及其制造方法
DE19531874C1 (de) 1995-08-30 1996-10-02 Daimler Benz Ag Seitenwandbaugruppe für eine Kraftfahrzeugkarosserie
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2921060B1 (fr) 2007-09-14 2012-06-15 Novexel Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires
ES2533826T3 (es) 2008-01-18 2015-04-15 Merck Sharp & Dohme Corp. Inhibidores de beta-lactamasa
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
WO2010126820A2 (en) 2009-04-30 2010-11-04 Merck Sharp & Dohme Corp. Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
JP2012122603A (ja) 2010-11-15 2012-06-28 Nifco Inc コネクタ装置
US8772490B2 (en) 2010-12-22 2014-07-08 Meiji Seika Pharma Co., Ltd. Optically active diazabicyclooctane derivatives and process for preparing the same
SI2657234T1 (sl) 2010-12-22 2017-06-30 Meiji Seika Pharma Co., Ltd. Derivat optično-aktivnega diazabiciklooktana in metoda za njegovo izdelavo
JP6023800B2 (ja) 2011-06-17 2016-11-09 アストラゼネカ アクチボラグ trans−7−オキソ−6−(スルホオキシ)−1,6−ジアザビシクロ[3,2,1]オクタン−2−カルボキサミドとその塩が含まれる複素環式化合物を製造するための方法
EP2748165B1 (en) 2011-08-27 2016-11-02 Wockhardt Limited 1,6-diazabicyclo[3,2,1]octan-7-one derivatives and their use in the treatment of bacterial infections.
PT2872510T (pt) 2011-08-30 2017-03-01 Wockhardt Ltd Derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e seu uso no tratamento de infeções bacterianas
AU2012310136B2 (en) 2011-09-13 2016-07-07 Wockhardt Limited Nitrogen containing compounds and their use
US8796257B2 (en) * 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
US9505761B2 (en) 2011-12-02 2016-11-29 Fedora Pharmaceuticals Inc. Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors
EP2857401B8 (en) 2012-05-30 2019-11-20 Meiji Seika Pharma Co., Ltd. NOVEL ß-LACTAMASE INHIBITOR AND METHOD FOR PRODUCING SAME
KR101946107B1 (ko) * 2012-08-25 2019-02-08 욱크하르트 리미티드 1,6-디아자비시클로〔3,2,1〕옥탄-7-온 유도체 및 세균 감염의 치료에서의 이의 용도
US10000491B2 (en) * 2013-09-24 2018-06-19 Meiji Seika Pharma Co., Ltd. Process for producing diazabicyclooctane derivative and intermediate thereof
NZ719568A (en) 2013-10-08 2018-06-29 Meiji Seika Pharma Co Ltd Crystals of diazabicyclooctane derivative and production method for crystals of diazabicyclooctane derivative
IN2014MU01192A (es) 2014-03-29 2015-10-02 Wockhardt Ltd
AU2015355970B2 (en) 2014-12-05 2020-05-21 Meiji Seika Pharma Co., Ltd. Method for producing crystals of diazabicyclooctane derivative and stable lyophilized preparation

Also Published As

Publication number Publication date
CN105612159A (zh) 2016-05-25
NZ757222A (en) 2021-12-24
BR112016006266A2 (es) 2017-08-22
ZA201602054B (en) 2019-06-26
NZ757220A (en) 2021-12-24
KR20160065871A (ko) 2016-06-09
RU2019115119A3 (es) 2022-04-26
HUE051925T2 (hu) 2021-04-28
US20200181143A1 (en) 2020-06-11
EP3613740A1 (en) 2020-02-26
BR112016006266B1 (pt) 2022-11-16
AR132030A2 (es) 2025-05-21
SG11201602723RA (en) 2016-05-30
US12221443B2 (en) 2025-02-11
NZ719568A (en) 2018-06-29
EP3067355B1 (en) 2020-12-16
US20250059191A1 (en) 2025-02-20
ES2842225T3 (es) 2021-07-13
CA3110803C (en) 2022-09-27
US20160272641A1 (en) 2016-09-22
CA2926071A1 (en) 2015-04-16
IL289275B (en) 2022-10-01
TW201605855A (zh) 2016-02-16
AR097971A1 (es) 2016-04-20
IL289275A (en) 2022-02-01
NZ757221A (en) 2021-12-24
RU2695219C2 (ru) 2019-07-22
KR102388529B1 (ko) 2022-04-20
MY199066A (en) 2023-10-12
JPWO2015053297A1 (ja) 2017-03-09
CN111153903A (zh) 2020-05-15
US20190031659A1 (en) 2019-01-31
JP2020007366A (ja) 2020-01-16
RU2016116501A3 (es) 2018-07-12
IL289275B2 (en) 2023-02-01
RU2016116501A (ru) 2017-11-15
MX2016004506A (es) 2016-06-16
RU2019115119A (ru) 2019-05-29
EP3067355A4 (en) 2017-04-26
DK3067355T3 (da) 2021-01-04
NZ743374A (en) 2021-12-24
WO2015053297A1 (ja) 2015-04-16
AU2014332960A1 (en) 2016-05-26
EP3067355A1 (en) 2016-09-14
JP6617029B2 (ja) 2019-12-04
AR132029A2 (es) 2025-05-21
JP2021193107A (ja) 2021-12-23
AU2014332960B2 (en) 2018-03-29
HK1219479A1 (zh) 2017-04-07
HK1250030A1 (en) 2018-11-23
EP3299370B1 (en) 2021-11-24
BR122022016622B1 (pt) 2023-11-07
JP6995810B2 (ja) 2022-01-17
KR102487297B1 (ko) 2023-01-12
US11414417B2 (en) 2022-08-16
EP3613741A1 (en) 2020-02-26
EP3299370A1 (en) 2018-03-28
MX361659B (es) 2018-12-13
US20220348578A1 (en) 2022-11-03
ES2901198T3 (es) 2022-03-21
CA3110803A1 (en) 2015-04-16
CA2926071C (en) 2021-11-09
KR20220054694A (ko) 2022-05-03
TWI673269B (zh) 2019-10-01
JP7182677B2 (ja) 2022-12-02
US10604522B2 (en) 2020-03-31
MX383661B (es) 2025-03-14
IL244969A0 (en) 2016-05-31
US10131665B2 (en) 2018-11-20
IL244969B (en) 2022-01-01

Similar Documents

Publication Publication Date Title
AR132028A2 (es) Proceso de producción de un compuesto intermediario de diazabiciclo [3.2.1]octano-2-carboxamida
ECSP18010065A (es) Proceso para la producción de cannabidiol y delta-9-tetrahidrocannabinol
AR086206A1 (es) Proceso para preparar un precursor de catalizador y proceso de sintesis de hidrocarburos
SA515360817B1 (ar) ألكلة هيدروجينية لمركبات عطرية ألكيلية لإنتاج مواد ملدنة
MX361183B (es) Derivados de 1,4-ciclohexilamina y procesos para la preparación de los mismos.
UY35641A (es) PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO)
BR112014026053A2 (pt) método de preparo de para-xileno a partir de biomassa
AR096238A1 (es) Proceso para preparar derivados de 3-((2s,5s)-4-metilen-5-(3-oxopropil)tetrahidrofuran-2-il)propanol e intermediarios útiles para el mismo
NZ718607A (en) Synthetic route to 2’-deoxy-2’,2’-difluorotetrahydrouridines
BR112018005199A2 (pt) composições de duas ou múltiplas cabeças úteis para o transporte de cadeia e processo para preparar as mesmas
EA201391795A1 (ru) Композиция и способ для повышения добычи углеводородов
BR112015007737A2 (pt) complexo oxo-nitrogenado de cobalto, sistema catalítico compreendendo o dito complexo oxo-nitrogenado e processo para a (co)polimerização de dienos conjugados
BR112016012971A2 (pt) Complexo de metal-ligante, catalisador e processo para preparar uma poliolefina
MX374783B (es) Procedimiento para purificar darbepoyetina alfa.
WO2014127418A8 (en) Conjugate compound and uses of same
WO2014087208A3 (en) A process of preparing alcaftadine
MX2016005223A (es) Tinturas dispersas, su preparacion y su uso.
MY191759A (en) Processes for the preparation of pyrimidinylcyclopentane compounds
GB2523674A (en) Compounds as inhibitor of DNA double-strand break repair, methods and applications thereof
SA112330994B1 (ar) عملية جديدة لتخليق إيفابردين وأملاح الإضافة الخاصة به مع حمض مقبول صيدلانياً
WO2014178064A3 (en) "an improved process for the preparation of fluvoxamine maleate"
JO3276B1 (ar) طريقة لتخليق 3، 4-داي ميثوكسي باي سيكلو [4. 2. 0] أوكتا-5،3،1-تراي إين-7-كربونيتريل واستخدامها لتخليق ايفابرادين والأملاح المضافة منه مع حمض مقبول صيدلانيا.
MX2013002990A (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
MX2016005222A (es) Tinturas acidas, proceso para su produccion y su uso.
RU2012136787A (ru) Способ получения микрокапсул гетероциклических соединений триазинового ряда